Orthopediatrics Corp Earnings Call Shows Profitable Momentum

Orthopediatrics Corp ((KIDS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Orthopediatrics Corp’s latest earnings call struck an upbeat tone, with management emphasizing accelerating growth, improved profitability metrics, and mounting momentum from a rich pipeline of new products. While executives acknowledged ongoing losses and execution risks, they framed these as manageable trade-offs in pursuit of a stronger, higher-margin growth profile over the next several years.

Record Patient Volumes Underscore Mission and Demand

Orthopediatrics highlighted that its solutions supported treatment of a record 45,000 children in the first quarter, bringing its cumulative patient count to nearly 1.4 million. Management leaned on these figures to reinforce the company’s specialized focus on pediatric orthopedics and to argue that the underlying demand for its portfolio remains robust.

Double-Digit Revenue Growth in U.S. and Abroad

The company posted revenue of $59.4 million in Q1 2026, up 13% year over year, signaling solid top-line momentum despite some weather-related headwinds. U.S. revenue grew 11% to $45.3 million and represented about 76% of total sales, while international revenue climbed roughly 22% to $14.1 million and now contributes about 24% of the mix.

Guidance Raise Marks Confidence in Growth Trajectory

Management lifted full-year 2026 revenue guidance to a range of $263 million to $267 million, equating to 11% to 13% growth and reflecting confidence in execution. The company also reaffirmed goals for roughly $25 million in adjusted EBITDA this year, about $10 million of set deployments, and achieving full-year free cash flow breakeven.

Adjusted EBITDA Swings Back to Positive Territory

A key milestone was the return to positive adjusted EBITDA, which reached $2.2 million in Q1, compared with a loss of $0.4 million in the prior-year period. Management framed this as early evidence of operating leverage emerging from higher revenue, richer product mix, and better cost discipline, even as they continue investing in growth.

Improving Cash Burn and Enhanced Liquidity Cushion

Free cash flow usage improved markedly, with $5.0 million used in Q1 versus $8.4 million a year ago, a roughly 40% improvement. The company ended the quarter with $50.9 million in cash, short-term investments, and restricted cash and added access to a $20 million delayed-draw term loan, bolstering its liquidity position.

New Product Super Cycle Drives Pricing and Margins

Orthopediatrics reported strong early beta demand for its 3P Hip and Vertiglyde systems, with the 3P Small Mini beta slated to launch late in the second quarter. Additional products, including Veraxis and Ellie, are targeted for first-in-patient or first surgeries by year-end, with management pointing to higher average selling prices and margin expansion as this portfolio scales.

Specialty Bracing Delivers 20% Plus Growth and Expansion

The OPSB specialty bracing segment delivered more than 20% growth in the quarter, supported by solid same-store performance and faster-than-planned clinic expansion. The company remains on track toward its goal of reaching 27 territories by 2027 through a mix of greenfield openings and selective acqui-hire opportunities in key markets.

European Regulatory Wins Unlock Growth Optionality

Orthopediatrics secured full EU MDR approval for its trauma and deformity, scoliosis, and external fixation portfolios, clearing a major regulatory hurdle in Europe. Management expects these approvals to enable broader commercialization across the region and to contribute to improved growth in the EMEA segment in the second half of 2026.

Scoliosis Portfolio Benefits from Vertiglyde and Technology

The scoliosis franchise generated $15.4 million in revenue, up 13% year over year, driven by strength in the Response and Vertiglyde systems alongside 7D navigation technology. Roughly 80 surgeons have already been trained on Vertiglyde, and given strong demand, the company plans to move from beta to full market release in the second quarter.

Digital Tools, Robotics, and AI Initiatives Gain Traction

Management highlighted early beta deployments of Playbook, a digital workflow platform designed to streamline surgical planning and execution. The company also completed its first pediatric cases with the Iota Motion robot and is progressing AI initiatives, targeting six to eight specialized AI agents aimed at clinical and operational efficiencies.

Weather Delays Temporarily Shifted Demand into Q2

Winter weather disruptions in January and February forced temporary shutdowns of some orthotics and prosthetics clinics, leading to a softer start to the quarter. Many of these appointments were rescheduled into March and April, effectively shifting some activity from Q1 into Q2 and modestly dampening first-quarter reported results.

Persistent Net Losses Highlight Path Still to Profitability

Despite operational gains, the company continued to post losses, with GAAP net loss per share of $0.45 versus $0.46 a year ago and non-GAAP net loss per share of $0.42, slightly worse than $0.39 previously. Management emphasized that they are prioritizing margin expansion and scale, but acknowledged that per-share profitability remains a work in progress.

Rising Operating Costs Could Pressure Margins if Growth Slows

Total operating expenses increased by $2.5 million, or 5% year over year, reaching $51.7 million in the quarter, reflecting continued investment across the business. Sales and marketing costs rose 11% to $18.5 million, mainly on higher commissions and volume, while general and administrative expenses ticked up 2% to $31.0 million.

Strategic Shift to Higher-Value Sets Lowers Capital Deployed

Set deployments totaled $2.3 million in Q1 2026, down from $3.6 million a year ago, a roughly 36% decline that management described as intentional. The company is prioritizing newer, higher-ASP systems that require less capital per dollar of revenue, but acknowledged that lower deployments can influence the cadence of implant revenue recognition.

Cash Flow Still Negative with Expected Quarterly Volatility

Although free cash flow improved significantly, it remained negative at $5.0 million in the quarter and management cautioned that quarterly trends will likely remain uneven. They expect a mix of negative and positive quarters on the way to meeting their goal of full-year free cash flow breakeven, underscoring a gradual transition rather than an abrupt shift.

Execution and Timing Remain Key Risk Factors

Management flagged several execution and timing risks, including set availability, regulatory processes in various markets, and the pace of scaling new product launches. Growth in areas such as European expansion, 3P system rollouts, and Veraxis and Ellie adoption will depend on smooth logistics and timely approvals, which could constrain revenue if delayed.

Guidance Signals Confidence in Multi-Year Growth Story

The company’s updated outlook calls for 2026 revenue of $263 million to $267 million, 11% to 13% growth, and about $25 million in adjusted EBITDA alongside full-year free cash flow breakeven and around $10 million of set deployments. Management linked this guidance to ongoing share gains, strong OPSB growth, accelerating international performance, and a multi-year product cycle expected to lift pricing, margins, and capital efficiency.

Orthopediatrics’ earnings call painted a picture of a specialist company leaning into a product-driven growth cycle while steadily tightening its financial profile. With double-digit revenue growth, a return to positive adjusted EBITDA, and a guidance raise, management argued that strategic momentum outweighs near-term losses and execution risks, leaving investors focused on whether the company can sustain its pace through 2026 and beyond.